Collaboration Details

Print  Close


Title of Collaborative Activity:

A5349/TBTC S31 - Rifapentine - Containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-Label, Controlled Phase 3 Clinical Trial

Description of Collaborative Activity:

The purpose of this research initiative is to provide scientific discovery to improve patient care and safety by reducing the duration of treatment for drug-susceptible pulmonary tuberculosis to 4 months by using new regimens, including high-dose rifapentine.

Type of Collaborative Activity:

Research Initiative

Year the Collaborative Activity Originated:

2015

NIH Participating Institutes/Centers/Office of the Director:

NIAID

HHS Agency Collaborators on this Activity:

CDC